Vector: Smallpox vaccine

2024: Product Announcement

The Center for Virology and Biotechnology "Vector" of Rospotrebnadzor in October 2024 launched the production of a vaccine against smallpox. The vaccine developed by the scientific center has already received registration. At the first stage, it is planned to release limited batches for vaccination of representatives of risk groups.

According to Interfax, Deputy General Director of Vector Elena Nechaeva said that the full cycle of vaccine production is about 3.5 months, and the first doses will go into civilian circulation in early 2025, after receiving all the necessary permits. The production facilities of the center allow the release of from 5 to 10 thousand doses. First of all, the vaccine will be intended for employees of the "Vector" itself and other persons at risk.

Freepik

In addition, Nechaeva noted that the industrial partner of Vector is the Geropharm company, which will be engaged in the production of industrial vaccine series. To do this, she will have to release three trial series, which will be subjected to strict control. According to Nechaeva, after successfully passing the checks, the series data will be included in the registration documents of the Vector Center.

The vaccine developed by Vector belongs to the fourth generation and was registered Ministry of Health Russia on November 11, 2022. The vaccine was created using genetically engineered methods and includes six inactivated virulence genes, which allows you to achieve a high level of protection against the disease.

The vaccine production technology has already been transferred to the partner, and the Geropharm company is starting preparations for mass production.^[1]

Notes